{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:39:09Z","timestamp":1784263149258,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ek0109594s0101, JP23ek0109594s0102, and JP24ek0109594s0103"],"award-info":[{"award-number":["JP22ek0109594s0101, JP23ek0109594s0102, and JP24ek0109594s0103"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["23K15198"],"award-info":[{"award-number":["23K15198"]}]},{"name":"JSPS KAKENHI","award":["25K11465"],"award-info":[{"award-number":["25K11465"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds and objectives<\/jats:title>\n                    <jats:p>Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disorder, and its long-term clinical outcomes, underlying determinants, and temporal dynamics of serum autoantibody levels remain poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective observational study comprised 64 patients diagnosed with aPAP, all of whom had been monitored for a minimum of three years following disease onset. Clinical courses were evaluated using disease severity score (DSS), based on arterial oxygen tension and respiratory symptoms. Serum anti\u2013granulocyte-macrophage colony-stimulating factor (GM-CSF) IgG autoantibody (\u03b1GM) levels were quantified by enzyme-linked immunosorbent assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 64 patients with any DSS, 45.3% showed clinical improvement, 40.6% remained stable, and 14.1% experienced deterioration over median follow-up period of 7.8 years. In a binary logistic regression analysis excluding patients with an initial DSS of 1, for whom improvement was not feasible, higher initial DSS, higher baseline % forced vital capacity, and the absence of fibrotic patterns on computed tomography were identified as significant explanatory variables associated with DSS improvement, whereas whole lung lavage (WLL) and GM-CSF inhalation were not in the comparison of the initial and final DSS. Longitudinal assessment of serum \u03b1GM levels in 52 patients revealed a decline in 98% of them (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200951) with an estimated antibody half-life of 3.5 years. GM-CSF inhalation therapy was significantly associated with lower final antibody levels adjusted for initial level and the interval between the initial and final measurements by analysis of covariance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The overall decline in \u03b1GM levels observed in this study may suggest a favorable or stable long-term prognosis in aPAP; however, further longitudinal investigations are warranted to confirm this presumed association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04274-w","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:52:59Z","timestamp":1773193979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A long-term observational study on autoimmune pulmonary alveolar proteinosis revealed a sustained and generalized decrease in serum autoantibody levels"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0172-6228","authenticated-orcid":false,"given":"Etsuro","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Katano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-4653","authenticated-orcid":false,"given":"Satoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"6","key":"4274_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1084\/jem.190.6.875","volume":"190","author":"T Kitamura","year":"1999","unstructured":"Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte\/macrophage colony-stimulating factor. J Exp Med. 1999;190(6):875\u201380. https:\/\/doi.org\/10.1084\/jem.190.6.875.","journal-title":"J Exp Med"},{"issue":"5","key":"4274_CR2","doi-asserted-by":"publisher","first-page":"2400725","DOI":"10.1183\/13993003.00725-2024","volume":"64","author":"C McCarthy","year":"2024","unstructured":"McCarthy C, Bonella F, O\u2019Callaghan M, Dupin C, Alfaro T, Fally M, et al. European respiratory society guidelines for the diagnosis and management of pulmonary alveolar proteinosis. Eur Respir J. 2024;64(5):2400725. https:\/\/doi.org\/10.1183\/13993003.00725-2024.","journal-title":"Eur Respir J"},{"issue":"1","key":"4274_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-019-0066-3","volume":"5","author":"BC Trapnell","year":"2019","unstructured":"Trapnell BC, Nakata K, Bonella F, Campo I, Griese M, Hamilton J, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers. 2019;5(1):16. https:\/\/doi.org\/10.1038\/s41572-019-0066-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"4274_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1816216","volume":"381","author":"R Tazawa","year":"2019","unstructured":"Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, et al. Inhaled GM-CSF for pulmonary alveolar proteinosis. N Engl J Med. 2019;381(10):923\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1816216.","journal-title":"N Engl J Med"},{"issue":"17","key":"4274_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1913590","volume":"383","author":"BC Trapnell","year":"2020","unstructured":"Trapnell BC, Inoue Y, Bonella F, Morgan C, Jouneau S, Bendstrup E, et al. Inhaled Molgramostim therapy in autoimmune pulmonary alveolar proteinosis. N Engl J Med. 2020;383(17):1635\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1913590.","journal-title":"N Engl J Med"},{"issue":"8","key":"4274_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMoa2410542","volume":"393","author":"BC Trapnell","year":"2025","unstructured":"Trapnell BC, Inoue Y, Bonella F, Wang T, McCarthy C, Arai T, et al. Phase 3 trial of inhaled Molgramostim in autoimmune pulmonary alveolar proteinosis. N Engl J Med. 2025;393(8):764\u201373. https:\/\/doi.org\/10.1056\/NEJMoa2410542.","journal-title":"N Engl J Med"},{"issue":"1","key":"4274_CR7","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41467-021-21011-y","volume":"12","author":"S Sakaue","year":"2021","unstructured":"Sakaue S, Yamaguchi E, Inoue Y, Takahashi M, Hirata J, Suzuki K, et al. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. Nat Commun. 2021;12(1):1032. https:\/\/doi.org\/10.1038\/s41467-021-21011-y.","journal-title":"Nat Commun"},{"issue":"7","key":"4274_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1164\/rccm.200708-1271OC","volume":"177","author":"Y Inoue","year":"2005","unstructured":"Inoue Y, Nakata K, Arai T, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2005;177(7):752\u201362. https:\/\/doi.org\/10.1164\/rccm.200708-1271OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"4274_CR9","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.rmed.2011.08.018","volume":"105","author":"F Bonella","year":"2011","unstructured":"Bonella F, Bauer PC, Griese M, Ohshimo S, Guzman J, Costabel U. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med. 2011;105(12):1908\u201316. https:\/\/doi.org\/10.1016\/j.rmed.2011.08.018.","journal-title":"Respir Med"},{"issue":"2","key":"4274_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2217\/bmm-2017-0362","volume":"12","author":"M Nishimura","year":"2018","unstructured":"Nishimura M, Yamaguchi E, Takahashi A, Asai N, Katsuda E, Ohta T, et al. Clinical significance of serum anti-GM-CSF autoantibody levels in autoimmune pulmonary alveolar proteinosis. Biomark Med. 2018;12(2):151\u20139. https:\/\/doi.org\/10.2217\/bmm-2017-0362.","journal-title":"Biomark Med"},{"issue":"4","key":"4274_CR11","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1164\/ajrccm.158.4.9712003","volume":"158","author":"T Takahashi","year":"1998","unstructured":"Takahashi T, Munakata M, Suzuki I, Kawakami Y. Serum and Bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 1998;158(4):1294\u20138. https:\/\/doi.org\/10.1164\/ajrccm.158.4.9712003.","journal-title":"Am J Respir Crit Care Med"},{"key":"4274_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1172-8-53","volume":"8","author":"F Bonella","year":"2013","unstructured":"Bonella F, Ohshimo S, Miaotian C, Griese M, Guzman J, Costabel U. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2013;8:53. https:\/\/doi.org\/10.1186\/1750-1172-8-53.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4274_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.2214\/ajr.15.14982","volume":"207","author":"M Akira","year":"2016","unstructured":"Akira M, Inoue Y, Arai T, Sugimoto C, Tokura S, Nakata K, et al. Pulmonary fibrosis on high-resolution CT of patients with pulmonary alveolar proteinosis. Am J Roentgenol. 2016;207(3):544\u201351. https:\/\/doi.org\/10.2214\/ajr.15.14982.","journal-title":"Am J Roentgenol"},{"issue":"12","key":"4274_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1164\/rccm.200906-0978oc","volume":"181","author":"R Tazawa","year":"2010","unstructured":"Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, et al. Inhaled granulocyte\/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010;181(12):1345\u201354. https:\/\/doi.org\/10.1164\/rccm.200906-0978oc.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"4274_CR15","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2009-05-155689","volume":"113","author":"K Uchida","year":"2009","unstructured":"Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Kochet DE, et al. Granulocyte\/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009;113(11):2547\u201356. https:\/\/doi.org\/10.1182\/blood-2009-05-155689.","journal-title":"Blood"},{"issue":"23","key":"4274_CR16","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM195806052582301","volume":"258","author":"SH Rosen","year":"1958","unstructured":"Rosen SH, Castleman B, Liebow AA, Enzinger FM, Hunt RTN. Pulmonary alveolar proteinosis. N Engl J Med. 1958;258(23):1123\u201342. https:\/\/doi.org\/10.1056\/NEJM195806052582301.","journal-title":"N Engl J Med"},{"issue":"2","key":"4274_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1164\/rccm.2109105","volume":"166","author":"JF Seymour","year":"2002","unstructured":"Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166(2):215\u201335. https:\/\/doi.org\/10.1164\/rccm.2109105.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"4274_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5603\/PiAP.2014.0028","volume":"82","author":"J Fijo\u0142ek","year":"2014","unstructured":"Fijo\u0142ek J, Wiatr E, Radzikowska E, Bestry I, Langfort R, Polubiec-Kownacka M, et al. Pulmonary alveolar proteinosis during a 30-year observation. Diagnosis and treatment. Pneumonol Allergol Pol. 2014;82(3):206\u201317. https:\/\/doi.org\/10.5603\/PiAP.2014.0028.","journal-title":"Pneumonol Allergol Pol"},{"issue":"6","key":"4274_CR19","doi-asserted-by":"publisher","first-page":"00314","DOI":"10.5603\/PiAP.2014.0028","volume":"10","author":"Y Guirriec","year":"2024","unstructured":"Guirriec Y, Luque-Paz D, Bernard G, Mabo A, Kerjouan M, M\u00e9nard C, et al. Pulmonary fibrosis in patients with autoimmune pulmonary alveolar proteinosis: a retrospective nationwide cohort study. ERJ Open Res. 2024;10(6):00314\u20132024. https:\/\/doi.org\/10.5603\/PiAP.2014.0028.","journal-title":"ERJ Open Res"},{"issue":"1","key":"4274_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1164\/rccm.201001-0008OC","volume":"182","author":"T Sakagami","year":"2010","unstructured":"Sakagami T, Beck D, Uchida K, Uchida K, Suzuki T, Carey BC, Nakata K, et al. Patient-derived granulocyte\/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010;182(1):49\u201361. https:\/\/doi.org\/10.1164\/rccm.201001-0008OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"4274_CR21","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1183\/09031936.00197710","volume":"38","author":"MS Kavuru","year":"2011","unstructured":"Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011;38(6):1361\u20137. https:\/\/doi.org\/10.1183\/09031936.00197710.","journal-title":"Eur Respir J"},{"issue":"1\u20132","key":"4274_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jim.2013.11.011","volume":"402","author":"K Uchida","year":"2014","unstructured":"Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, et al. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods. 2014;402(1\u20132):57\u201370. https:\/\/doi.org\/10.1016\/j.jim.2013.11.011.","journal-title":"J Immunol Methods"},{"issue":"2","key":"4274_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13730-022-00738-7","volume":"12","author":"T Kubota","year":"2023","unstructured":"Kubota T, Tsukimura T, Shiga T, Togawa T, Sakuraba H. Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy. CEN Case Rep. 2023;12(2):171\u20135. https:\/\/doi.org\/10.1007\/s13730-022-00738-7.","journal-title":"CEN Case Rep"},{"issue":"1","key":"4274_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","volume":"21","author":"SS Soldan","year":"2022","unstructured":"Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2022;21(1):51\u201364. https:\/\/doi.org\/10.1038\/s41579-022-00770-5.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4274_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41572-024-00580-4","volume":"10","author":"SE Leonhard","year":"2024","unstructured":"Leonhard SE, Papri N, Querol L, Rinaldi S, Shahrizaila N, Jacobs BC. Guillain-Barre syndrome. Nat Rev Dis Primers. 2024;10(1):97. https:\/\/doi.org\/10.1038\/s41572-024-00580-4.","journal-title":"Nat Rev Dis Primers"},{"issue":"7866","key":"4274_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283\u20138. https:\/\/doi.org\/10.1038\/s41586-021-03631-y.","journal-title":"Nature"},{"issue":"1","key":"4274_CR27","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1038\/s41467-024-53356-5","volume":"15","author":"AF Jernbom","year":"2024","unstructured":"Jernbom AF, Skoglund L, Pin E, Sj\u00f6berg R, Tegel H, Hober S, et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. Nat Commun. 2024;15(1):8941. https:\/\/doi.org\/10.1038\/s41467-024-53356-5.","journal-title":"Nat Commun"},{"issue":"1","key":"4274_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12985-024-02524-6","volume":"21","author":"T Iyadorai","year":"2024","unstructured":"Iyadorai T, Lim SH, Wong PL, Sii HL, P\u2019ng CK, Ee SS, et al. Clinical symptoms, comorbidities and health outcomes among outpatients infected with the common cold coronaviruses versus influenza virus. Virol J. 2024;21(1):251. https:\/\/doi.org\/10.1186\/s12985-024-02524-6.","journal-title":"Virol J"},{"issue":"1","key":"4274_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-024-02022-z","volume":"57","author":"N Sasa","year":"2025","unstructured":"Sasa N, Kojima S, Koide R, Hasegawa T, Namkoong H, Hirota T, et al. Blood DNA Virome associates with autoimmune diseases and COVID-19. Nat Genet. 2025;57(1):65\u201379. https:\/\/doi.org\/10.1038\/s41588-024-02022-z.","journal-title":"Nat Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04274-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:47:20Z","timestamp":1781639240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04274-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4274"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04274-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent and the study protocol was approved by the Ethics Committee of Aichi Medical University (12\u2013133, 2022\u2009\u2212\u2009146, 2023\u2009\u2212\u2009598, 2023\u2009\u2212\u2009151).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EY has received fees for scientific advice from Savara Inc. and honorarium for a lecture from Nobelpharma Co., Ltd. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}